Ali Akil1, Stephan Ziegeler2, Jan Reichelt1, Stephanie Rehers2, Omer Abdalla1, Michael Semik1, Stefan Fischer3. 1. Department of Thoracic Surgery and Lung Support, Klinikum Ibbenbueren, Ibbenbueren, Germany. 2. Department of Anesthesiology, Intensive Care Medicine and Pain Management, Klinikum Ibbenbueren, Ibbenbueren, NRW, Germany. 3. Department of Thoracic Surgery and Lung Support, Ibbenbueren General Hospital, Ibbenbueren, Germany.
Abstract
BACKGROUND: High morbidity and mortality are frequently reported in intensive care patients suffering from severe sepsis with systemic inflammation. With the development of severe respiratory failure, extracorporeal membrane oxygenation (ECMO) is often required. In this study, cytokine adsorption therapy in combination with ECMO is applied in patients with acute respiratory distress syndrome (ARDS) due to severe pneumogenic sepsis. The efficacy of this therapy is evaluated compared with a historical cohort without hemoadsorption therapy. METHODS: Between January and May 2018, combined high-flow venovenous ECMO and CytoSorb therapy (CytoSorb filter connected to ECMO circuit) was applied in patients (n = 13) with pneumogenic sepsis and ARDS. These patients were prospectively included (CytoSorb group). Data from patients (n = 7) with pneumogenic sepsis and ECMO therapy were retrospectively analyzed (control group). RESULTS: All patients survived in the CytoSorb group, where the 30-day mortality rate reached 57% in the control group. After CytoSorb therapy, we instantly observed a significant reduction in procalcitonin (PCT) and C-reactive protein (CRP) levels compared with the control group. Within 48 hours, the initial high doses of catecholamine could be weaned off only in the CytoSorb group. CONCLUSIONS: Our results indicate that CytoSorb in combination with ECMO is an effective therapy to prevent escalation of sepsis with rapid weaning off high-dose catecholamine infusions and quick reduction in PCT and CRP levels. Optimal timing of immunomodulatory therapy and impact on ECMO-related inflammation still need to be furtherly investigated. Thieme. All rights reserved.
BACKGROUND: High morbidity and mortality are frequently reported in intensive care patients suffering from severe sepsis with systemic inflammation. With the development of severe respiratory failure, extracorporeal membrane oxygenation (ECMO) is often required. In this study, cytokine adsorption therapy in combination with ECMO is applied in patients with acute respiratory distress syndrome (ARDS) due to severe pneumogenic sepsis. The efficacy of this therapy is evaluated compared with a historical cohort without hemoadsorption therapy. METHODS: Between January and May 2018, combined high-flow venovenous ECMO and CytoSorb therapy (CytoSorb filter connected to ECMO circuit) was applied in patients (n = 13) with pneumogenic sepsis and ARDS. These patients were prospectively included (CytoSorb group). Data from patients (n = 7) with pneumogenic sepsis and ECMO therapy were retrospectively analyzed (control group). RESULTS: All patients survived in the CytoSorb group, where the 30-day mortality rate reached 57% in the control group. After CytoSorb therapy, we instantly observed a significant reduction in procalcitonin (PCT) and C-reactive protein (CRP) levels compared with the control group. Within 48 hours, the initial high doses of catecholamine could be weaned off only in the CytoSorb group. CONCLUSIONS: Our results indicate that CytoSorb in combination with ECMO is an effective therapy to prevent escalation of sepsis with rapid weaning off high-dose catecholamine infusions and quick reduction in PCT and CRP levels. Optimal timing of immunomodulatory therapy and impact on ECMO-related inflammation still need to be furtherly investigated. Thieme. All rights reserved.
Authors: József Furák; Tibor Németh; Judit Lantos; Csongor Fabó; Tibor Géczi; Noémi Zombori-Tóth; Dóra Paróczai; Zalán Szántó; Zsolt Szabó Journal: Front Surg Date: 2022-05-20
Authors: Marina Rieder; Fabian Schubach; Claudia Schmoor; Caroline von Spee-Mayer; Tobias Wengenmayer; Jonathan Rilinger; Dawid Staudacher; Christoph Bode; Daniel Duerschmied; Alexander Supady Journal: BMJ Open Date: 2021-01-17 Impact factor: 2.692
Authors: Christina Scharf; Ines Schroeder; Michael Paal; Martin Winkels; Michael Irlbeck; Michael Zoller; Uwe Liebchen Journal: Ann Intensive Care Date: 2021-07-22 Impact factor: 6.925
Authors: Travis C Geraci; Zachary N Kon; Nader Moazami; Stephanie H Chang; Julius Carillo; Stacey Chen; Anthony Fargnoli; Marjan Alimi; Harvey Pass; Aubrey Galloway; Deane E Smith Journal: J Card Surg Date: 2021-07-04 Impact factor: 1.778